Overview
Streamline your pre-clinical development with flexible synthesis of mRNA services. Our end-to-end solutions—from gene synthesis to IVT mRNA—deliver research-ready material in as fast as 3 weeks, supporting both in vitro and in vivo studies.
Technically Superior mRNA
• dsRNA controlled to minimize immune activation
• Free-to-operate backbone available
• Tailored testing packages
Cost-Efficient without Quality Compromise
• Bulk discounts for multi-project deals
• Value-added services – free consultations
IP Solution Provider
• Patent-protected alternatives: Our proprietary caps, enzymes, and LNPs come with clear IP ownership, eliminating legal uncertainties.
• Affordable access: Transparent licensing fees, no hidden royalties.
• Drop-in replacements: Compatible with industry-standard processes
Scalable & Phase-Ready Manufacturing
• Seamless scale-up: GLP-grade batches up to 100 mg, GMP-grade CDMO services beyond
• Consistent quality: smooth transition from pre-clinical to clinical
Need help with a custom order?
CONTACT US
Workflow
Gene Synthesis
• Fast turnaround
• Highest level of accuracy
Plasmid Preparation
• FTO* plasmid backbone available
• Stable Poly (A) tail
*FTO: Free-to-operate
mRNA Synthesis
• dsRNA reduced synthesis options
• Non-infringing caps, enzymes options
Purification
• Diverse purification options: LiCl, silica membrane or oligo (dT)
Strict QC
• Comprehensive testing panels to ensure the purity and integrity
5’ Cap Options
Modified NTP Options
Poly(A) Tail Options
Co-transcriptional capping:
• Partner-supplied Cap (Cap 1 structure)
• AG
• AG (3' OMe)
• AU
• Proprietary AG analog (FTO- guaranteed, licensable IP)
Enzymatic capping:
• Vaccine capping system
• m1ψ-UTP
• ψ-UTP
• m5C
• m6A
• 100A tail (recommended)
• Custom tail ≤ 120A
Service
Quality Control
Screening Grade Research Grade Preclinical Grade
RNA Type mRNA, saRNA mRNA, saRNA mRNA, saRNA
Sequence Length* 0-15 kb 0-15 kb 0-15 kb
Scale 0.2 mg & 0.5 mg 1-10 mg 20-100 mg
Turnaround Time 7-10 Business Days 7-10 Business Days 10-12 Business Days
Deliverable • Individual Cryotubes
• ROA • Individual Cryotubes
• ROA • Individual Cryotubes
• ROA
* Additional fee may be charged for sequence longer than 7 kb.
FAQ
What are the key differences among your “Screening Grade”, “Research Grade” and “Preclinical Grade” mRNA?
All three grades are simple, fast, and low-cost to operate, and are produced to phase-appropriate standards. The key difference lies in the scale, purification process and release testing.
Screening Grade: For early-stage, high-throughput hit-to-lead screening, purified with LiCl precipitation or silica membrane, with typical QC tests (concentration, purity and integrity).
Research Grade: Ideal for lead-to-candidate optimization in vitro study or initial process development, purified with LiCl precipitation with standard QC tests (concentration, purity, integrity, endotoxin, pH).
Preclinical Grade: Produced via scalable industrial process by using Oligo (dT) chromatography with enhanced QC(concentration, purity, endotoxin, pH, integrity by CE full length analysis). Also suitable for animal studies.
Can I request specific modifications to the mRNA sequence or structure?
Yes. We offer a variety of common modifications, including but not limited to pseudo uridine (Ψ) or N1-methylpseudo uridine (m1Ψ) incorporation to reduce immunogenicity, custom cap analogs and custom poly(A) tail lengths. Please inquire during the quote design phase so we can propose the best strategy for your application.
What if I have a customization request?
Our mRNA experts have a long history of working with leading scientists on custom constructs and would be happy to discuss your unique application. Please contact with our sales team to customize your specific request.
Is the mRNA purified after synthesis, and what purification methods are used?
Yes, all mRNA products undergo diversified purification processes to fulfil end-user application scenarios. After IVT (in vitro transcription), The reaction mixture is first treated with DNase I to degrade the DNA template, then the mRNA is selectively precipitated by LiCl or loaded onto the silica column to pass through the membrane to remove impurities and other reaction components. The mRNA is captured and further eluted by applying RNase-free water. The final mRNA is sterile-filtered before aliquoting.
In the case of scale-up production, the industrialized Oligo (dT) chromatography and TFF are used as advanced purification methods to precisely capture and polish Poly(A) tailed mRNA.
How do you control dsRNA residues to minimize immunogenicity?
Based on high quality material/regent such as DNA plasmid and modified T7 polymerase enzyme, we employ an optimized IVT protocol, designed to reduce dsRNA formation. This approach significantly reduces dsRNA generation, helping to minimize nonspecific immune stimulation in cells and animals.
How is the mRNA capped, and what cap analog is used?
Our mRNA synthesis platform supports both co-transcriptional and enzymatic capping. For standard applications, we typically use high-performance Cap 1 analogs supplied by our partners, enhances translation efficiency and reduces immunogenicity.
Additionally, we provide a proprietary AG analog with FTO-guaranteed, licensing IP, available for licensing in clinical-stage and commercial mRNA therapeutic applications.
What quality control tests are performed on the mRNA?
Depending on different preclinical stages, a phase-appropriate QC protocol is applied across the most crucial quality attributes like RNA length, concentration, purity (A260/A280), pH, and endotoxin. This ensures you receive a high-quality mRNA product suitable for your research needs.
How do you quantify mRNA and assess its integrity?
For preclinical grade mRNA, we use automated capillary electrophoresis to accurately quantify the mRNA and evaluate its integrity. The results are documented in the Report of Analysis (RoA) provided with your mRNA product.
Can the endotoxins in the product be guaranteed?
Absolutely. Although our service is intended solely for in vitro studies, the endotoxin levels in products exceeding research grade are still subject to quality control in compliance with the method outlined in USP<85>. Each individual batch is tested using the LAL gel-clot method and released with endotoxin levels below 10 EU/mg RNA, ensuring the reliability and consistency of research-grade quality.
Founded in 2005, Quintarabio is a biotechnology company specializing in life-science technologies that enable and accelerate drug discovery and development through its innovative platforms.
